Skip to main content

Table 1 Demographical data of 30 patients with TPD regimen for advanced HER2-positive breast cancer

From: Use of the tumor-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to combination therapy with pertuzumab, trastuzumab, and docetaxel for advanced HER2-positive breast cancer

Parameters (n = 30)

Number of patients (%)

Age (years old)

62 (31–80)

Degree of progress

 Locally advanced/visceral metastases

10 (33.3%)/20 (66.7%)

Stage

 Stage IIIC/stage IV/recurrence

4 (13.3%)/11 (36.7%)/15 (50.0%)

Site of metastases

 Lung/bone/liver/brain/lymph node/soft tissue

11 (36.7%)/12 (40.0%)/7 (23.3%)/3 (10.0%)/12 (40.0%)/11 (36.6%)

Treatment line

 First/other

17 (56.7%)/13 (43.3%)

ER

 Negative/positive

18 (60.0%)/12 (40.0%)

PgR

 Negative/positive

20 (66.7%)/10 (33.3%)

Ki67

 Negative/positive

16 (55.2%)/14 (44.8%)

CD8

 Negative/positive

21 (70.0%)/9 (30.0%)

FOXP3

 Negative/positive

15 (50.0%)/15 (50.0%)

CFR

 Low/high

15 (50.0%)/15 (50.0%)

PD1

 Negative/positive

14 (46.7%)/16 (53.3%)

PD-L1

 Negative/positive

19 (63.3%)/11 (36.7%)

CD163

 Negative/positive

15 (50.0%)/15 (50.0%)

PTEN

 Negative/positive

17 (56.7%)/13 (43.3%)

LAG3

 Negative/positive

20 (66.7%)/10 (33.3%)

  1. TPD, trastuzumab, pertuzumab, docetaxel; HER2, human epidermal growth factor receptor 2; ER, estrogen receptor; PgR, progesterone receptor; FOXP3, forkhead box protein 3; CFR, CD8/FOXP3 ratio; PD1, programmed death 1; PD-L1, programmed death ligand-1; PTEN, phosphatase and tensin homolog; LAG3, lymphocyte activation gene 3